Our goal is to harness the potential of ADZE1.C to reprogram the tumor microenvironment and activate systemic anti-tumor immunity. Dr. Paola Grandi, CSO Adze

Adze Biotechnology, Inc. announced today the submission of a Human Research Ethics Committee (HREC) application to Bellberry Limited in Australia for the company’s Phase 1 clinical trial of Adze1.C in patients with metastatic melanoma.

ADZE is thrilled to welcome Dr. Paola Grandi to our team as we advance our pipeline of systemically deliverable oncolytic immunotherapies into the clinic.”— Sidney Hopps, Chief Executive Officer of Adze

This Notice of Allowance for broad recombinant adenovirus claims is another important step forward for ADZE, which further strengthens and expands our intellectual property portfolio.”— Sidney Hopps, Chief Executive Officer of ADZE

“The Adze Scientific Advisory Board will provide important counsel in the years ahead, with research & development”, Sidney Hopps, Co-Founder & CEO Adze   CORAL

“This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” – Sidney Hopps, Co-Founder & CEO

CORAL GABLES, FLORIDA, UNITED STATES, February 7, 2023 Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers recombinent human CD40 ligand locally into

CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023. The grant of this patent positions Adze to participate in the $18 billion annual checkpoint inhibitor market